Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; Marengo Therapeutics; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.

Gilead Sciences Inc.

RBC Capital analyst Brian Abrahams maintained a Hold rating on Gilead Sciences on July 23 and set a price target of $120.00. The company’s shares c...

Gilead Sciences (GILD) Gets a Hold from RBC Capital

Gilead Sciences ($GILD) announced an update on their ongoing clinical study. The Phase 3 study “A Phase 3, Randomized, Open-label Study to Evaluate...

Gilead Advances Long-Acting HIV Regimen in New Phase 3 Head‑to‑Head Trial

In a report released yesterday, Salveen Richter from Goldman Sachs maintained a Hold rating on Gilead Sciences, with a price target of $130.00. The...

Gilead Sciences (GILD) Gets a Hold from Goldman Sachs

Gilead Sciences ($GILD) announced an update on their ongoing clinical study. Gilead Sciences is launching a new study called “An Operationally Seam...

Gilead Targets Long-Acting HIV Regimens With New Injectable Study

Wells Fargo analyst Mohit Bansal maintained a Buy rating on Gilead Sciences yesterday and set a price target of $165.00. The company’s shares close...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	GILD	$134.32	+2.91%	6.94M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	GILD	$134.32	+2.9%	6.94M
3
4
5
6

GILD

GILD

Get Gilead Sciences Inc. Data in Excel

Get Gilead Sciences Inc. Data in Excel